Abstract
Objective
To explore the molecular mechanism of gemcitabine-resistance, the relative mRNA expression of five genes related to gemcitabine-resistance was detected in six lung cancer cell lines.
Methods
The total RNA was extracted from six lung cancer cell lines GLC-82, NCI-H460, A549, 95-C, 95-D and QG56. Then the cDNA was amplified by real-time quantitative PCR method to quantify the gene expression of RRM1, PTEN, ERCC1, dCK and CDA. The cytotoxicity of gemcitabine to cell lines was tested by MTT method.
Results
Among the detected six lung cancer cell lines, the mRNA level of RRM1, PTEN and ERCC1 in lung squamous cell line QG56 was highest, and the IC50 of gemcitabine to QG56 cell line was also highest.
Conclusion
The mRNA expression of RRM1, PTEN and ERCC1 was correlated, and the high expression of RRM1 was related to gemcitabine resistance of lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol, 2003, 30: 19–25.
Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics, 2002, 3: 763–780.
Pitterle DM, Kim YC, Jolicoeur EM, et al. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome, 1999, 10: 916–922.
Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity polymorphisms, population frequencies and clinical relevance. Lung cancer, 2005, 47: 183–192.
Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10: 1318–1325.
Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small cell lung cancer. J Clin Oncol, 2004, 22: 1878–1885.
Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64: 3761–3766.
Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control, 2003, 10: 297–305.
Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10: 4939–4943.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the Capital Medical Developing Foundation of China (No. 03028).
Rights and permissions
About this article
Cite this article
Lin, L., Liu, X., Rao, Y. et al. Detection of gemcitabine-resistant genes expression in lung cancer cell lines using real-time PCR. Chin. -Ger. J. Clin. Oncol. 7, 682–685 (2008). https://doi.org/10.1007/s10330-008-0127-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0127-7